These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15868022)

  • 41. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New models for pharmaceutical innovation in low-income countries.
    Ardal C; Iversen JH; Myhr K
    Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
    [No Abstract]   [Full Text] [Related]  

  • 44. Stimulating pharmaceutical research and development for neglected diseases.
    Mrazek MF; Mossialos E
    Health Policy; 2003 Apr; 64(1):75-88. PubMed ID: 12644330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services.
    Stebbins MR; Kaufman DJ; Lipton HL
    J Manag Care Pharm; 2005 May; 11(4):333-41. PubMed ID: 15871644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 48. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Brazil: agricultural modernisation and food production restructuring in the international crisis].
    Bertrand JP
    Tiers Monde (1960); 1985; 26(104):879-98. PubMed ID: 12267623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccines for low-income countries.
    MacLennan CA
    Semin Immunol; 2013 Apr; 25(2):114-23. PubMed ID: 23757292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
    Mutabingwa TK
    Acta Trop; 2005 Sep; 95(3):305-15. PubMed ID: 16098946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unresolved issues in contraceptive health policy.
    Reaves ND
    Health Care Women Int; 2002 Dec; 23(8):854-60. PubMed ID: 12487700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative study of European rare disease and orphan drug markets.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Health Policy; 2010 Oct; 97(2-3):173-9. PubMed ID: 20800761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Returns to R&D on new drug introductions in the 1980s.
    Grabowski HG; Vernon JM
    J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States.
    Gotham D; Moja L; van der Heijden M; Paulin S; Smith I; Beyer P
    Health Policy; 2021 Mar; 125(3):296-306. PubMed ID: 33402265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
    Mahalatchimy A; Faulkner A
    Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.